Glutamine metabolic reprogramming not only sustains tumor proliferation but also contributes to therapy resistance; inhibition of GLS or MYC sensitizes prostate cancer cells to radiotherapy, while autophagy enables glutamine-independent cells to withstand metabolic stress. This evidence concerns the gene MYC and prostate cancer.